Updated on 2024/12/03

写真a

 
uchiyama shotaro
 
Affiliation
Musashikosugi Hospital, Department of Neuropsychiatry, Assistant Professor
Title
Assistant Professor
External link

Papers

  • New-onset schizophrenia in an adolescent after COVID-19.

    Masatsugu Ishii, Kakusho C Nakajima-Ohyama, Hayato Saito, Tomoyuki Ohya, Shotaro Uchiyama, Mizuho Takahashi, Masanori Sakamaki, Akihiro Watanabe, Jun-Ichi Inoue, Tetsuro Sekine, Amane Tateno, Yasuhiro Kishi

    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi   2024.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Schizophrenia develops during adolescence. Maternal infections during the fetal period increase the incidence of schizophrenia in children, which suggests that the pathogenesis involves neuroinflammation. Here, we report a case of new-onset schizophrenia in a 16-year-old boy after COVID-19. After developing COVID-19, he entered a catatonic state 4 days later and was hospitalized. Benzodiazepines alleviated his catatonia, but hallucinations and delusions persisted. Encephalitis and epilepsy were excluded by magnetic resonance imaging (MRI), encephalography, and cerebrospinal fluid examination. Psychosis persisted after the virus titer declined and the inflammatory response subsided. Moreover, the patient exhibited delusions of control-a Schneider's first-rank symptom. Schizophrenia was diagnosed, and olanzapine improved his symptoms. He had a brief history of insomnia before COVID-19 but his symptoms did not satisfy the ultra-high-risk criteria. However, COVID-19 may have facilitated development of schizophrenia through neuroinflammation and volume reduction in the gray matter of the right medial temporal lobe. This case demonstrates that infectious diseases in adolescents should be carefully managed, to prevent schizophrenia.

    DOI: 10.1272/jnms.JNMS.2025_92-301

    PubMed

    researchmap

  • Usefulness of Gabapentin as an Alternative/Adjunct Therapy for Delirium: A Retrospective Observational Study.

    Kakusho Chigusa Nakajima-Ohyama, Yoshie Shizusawa, Shotaro Uchiyama, Yasuhiro Kishi, Hitoshi Tanimukai

    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi   91 ( 2 )   233 - 240   2024

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Antipsychotics are commonly used to treat delirium but can adversely affect the extrapyramidal and cardiac conduction systems. Antipsychotic use has also been reported to be associated with increased mortality in older adults. Therefore, alternative and adjunct medications for delirium are necessary. We retrospectively assessed the efficacy and safety of gabapentin (GBP) as an alternative and adjunct medication for delirium. METHODS: We retrospectively investigated the records of patients with delirium treated with GBP (71 patients; median age, 81 years; interquartile range, 76-87.5 years; 54.9% males) at a general hospital. We examined duration to delirium improvement, as assessed by the Intensive Care Delirium Screening Checklist (ICDSC) and DSM-5 criteria, as well as adverse events. RESULTS: The median (interquartile range) GBP dose was 200 mg (150-350 mg) /day. A total of 71.8% and 85.9% of the patients failed to meet the diagnostic criteria for delirium at 2 days and 5 days after initial administration, respectively (p<0.05). In subgroup analysis, patients with a history of epilepsy or cerebrovascular disease responded better to GBP than did those without such histories, suggesting that patients with abnormal/borderline neuronal activity respond to GBP even though they do not exhibit seizures. GBP did not induce extrapyramidal symptoms, cardiac conduction disturbances, hyperglycemia, or epilepsy but caused sleepiness and myoclonus. CONCLUSIONS: GBP may improve delirium with fewer adverse effects and may be a safe alternative or adjunct treatment for delirium. Dosage adjustment may be necessary to prevent sleepiness.

    DOI: 10.1272/jnms.JNMS.2024_91-214

    PubMed

    researchmap

Misc.

  • 現場を変えうるせん妄研究最前線 せん妄対策の医療全体へのValue

    岸 泰宏, 大山 覚照, 内山 翔太郎

    精神神経学雑誌   ( 2024特別号 )   S362 - S362   2024.6

     More details

    Language:Japanese   Publisher:(公社)日本精神神経学会  

    researchmap

  • 電気けいれん療法(ECT)における再発とドーパミントランスポーター(DAT)結合能の関連性

    内山 翔太郎, 大矢 智之, 坂寄 健, 野上 毅, 舘野 周, 荒川 亮介

    日本医科大学医学会雑誌   19 ( 4 )   398 - 398   2023.12

     More details

    Language:Japanese   Publisher:日本医科大学医学会  

    researchmap

  • 摂食障害・依存症におけるケトン体の役割についての基盤的研究

    大山 覚照, 坂井 敦, 早川 清雄, 明野 薫, 内山 翔太郎, 岸 泰宏, 荒川 亮介, 舘野 周

    総合病院精神医学   35 ( Suppl. )   S - 160   2023.11

     More details

    Language:Japanese   Publisher:(一社)日本総合病院精神医学会  

    researchmap

  • Clozapine投与により就労就学に繋がった若年統合失調症患者三症例

    内山 翔太郎, 朝山 健太郎, 舘野 周, 大久保 善朗

    精神神経学雑誌   ( 2019特別号 )   S474 - S474   2019.6

     More details

    Language:Japanese   Publisher:(公社)日本精神神経学会  

    researchmap

  • 高用量のclozapineが陰性症状の改善に寄与したと思われる破瓜型統合失調症の1例

    内山 翔太郎, 坂寄 健, 金 禹さん, 朝山 健太郎, 大久保 善朗

    精神神経学雑誌   118 ( 12 )   943 - 943   2016.12

     More details

    Language:Japanese   Publisher:(公社)日本精神神経学会  

    researchmap

  • 老年期の重症うつ病の回復過程にみられた妄想の階層性 電気けいれん療法による治療経過に基づく考察

    平澤 俊之, 内山 翔太郎, 坂寄 健, 金 禹さん, 上田 諭, 大久保 善朗

    精神神経学雑誌   118 ( 9 )   719 - 719   2016.9

     More details

    Language:Japanese   Publisher:(公社)日本精神神経学会  

    researchmap

  • 近赤外線スペクトロスコピーを用いたm-ECT治療前後の気分障害患者の前頭側頭波形パターンに関する予備的検討

    肥田 道彦, 秋山 友美, 永田 恵理香, 太田 杏奈, 内山 翔太郎, 岩本 康夫, 安田 毅, 鈴木 清人, 新貝 慈利, 池森 紀夫, 下田 健吾, 木村 真人

    総合病院精神医学   28 ( 1 )   55 - 56   2016.1

     More details

    Language:Japanese   Publisher:(一社)日本総合病院精神医学会  

    researchmap

▼display all